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Abstract The 7th conference of the American College
of Chest Physicians (ACCP7) provides recommendations
on the type, dose, and duration of thromboprophylaxis in
hospitalized patients at risk of venous thromboembolism
(VTE), but the extent to which hospitals follow these
criteria has not been well studied. Discharge and billing
records for patients admitted to any of 16 acute-care
hospitals from January 2005 to December 2006 were
obtained. Patients 18 years or older who had an inpatient
stay C2 days and no apparent contraindications for throm-
boprophylaxis were grouped into the categories of critical
care, surgery and medically ill before being assessed for
additional VTE risk factors based on the diagnostic criteria
outlined in ACCP7. For patients at risk, the recommended
type (mechanical or pharmacologic), dose, and duration of
thromboprophylaxis was identiﬁed based on the guidelines
and compared to the regimen actually received, if any.
Among the 258,556 hospitalized patients, 68,278 (26.4%)
were determined to be at risk of VTE without apparent
contraindications for thromboprophylaxis. The proportions
of patients who received the appropriate type, dose, and
duration of thromboprophylaxis were 10.5, 9.8, and 17.9%
for critical care, medical, and surgical patients, respectively.
Of those at risk, 36.8% received no thromboprophylaxis
and an additional 50.2% received thromboprophylaxis
deemed inappropriate for one or more reasons. The imple-
mentation of ACCP7 guidelines for type, dosage, and
duration of thromboprophylaxis is low in patients at risk of
VTE. There is a need for physicians and health systems to
improve awareness and implementation of recommended
thromboprophylaxis.
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Introduction
The American College of Chest Physicians (ACCP) has
issued guidelines for the prevention of venous thromboem-
bolism (VTE) since 1986. The 7th and most recent update of
these guidelines (ACCP7), published in 2004, are based on a
comprehensiveassessmentoftheliteratureonriskfactorsand
effective thromboprophylaxis regimens [1]. These guidelines
identify speciﬁc groups of medical and surgical patients at
risk of VTE and provide recommendations for the type
(mechanical, pharmacologic, or combination), dose and dura-
tionofthrombo-prophylacticmeasures.TheJointCommission
on Accreditation of Healthcare Organizations and the National
Quality Forum have recognized the importance of using
thromboprophylaxis to prevent VTE in hospitalized patients
[2]. Moreover, in 2007 two new quality indicators were added
to Medicare’s Surgical Care Improvement Project: Thrombo-
prophylaxis ordered for surgery patient, and thromboprophy-
laxis within 24 h pre/post surgery[3].
Despite the long-standing availability of evidence-based
guidelinesforthromboprophylaxis,compliancewiththesein
hospitalized patients at risk has remained low. Previous
retrospectivestudiesusingpatientchartreviewshaveshown
that25to84%ofhospitalizedpatientsareatriskofVTEand
that only 23 to 46% of these patients receive any form of
thromboprophylaxis [4–10]. However, assessments of evi-
dence-based thromboprophylaxis are more clinically
meaningful when all of the criteria for appropriate throm-
boprophylaxis are measured. To date, no studies have
assessed the appropriateness of thromboprophylaxis against
ACCP7recommendationsforthe type,dose,anddurationof
therapy. Assessments using electronic discharge-summary
and billing records offer the advantage of including large
samples of patients at risk for VTE and the ability to assess
not only the rate of thromboprophylaxis but also its appro-
priateness with respect to type, dose and duration. The pri-
maryaimofthisprojectwas tosupportqualityimprovement
efforts at selected US hospitals by measuring implementa-
tion of ACCP7 guidelines for type, dose, and duration of
thromboprophylaxis across a broad range of medical and
surgical conditions.
Methods
Data source
The Venous Thromboembolism Study to Assess the Rate
of Thromboprophylaxis (VTE START) was part of a
quality improvement initiative designed to help hospitals
assess and improve their use of appropriate thrombopro-
phylaxis. A Steering Committee of researchers and clinical
experts in thromboprophylaxis were responsible for the
design and implementation of the project. Participation was
offered by the Steering Committee to a convenience sam-
ple of acute-care hospitals of various sizes in urban and
rural areas of the Midwest and Southwest. Of 16 that
participated, 13 hospitals were afﬁliated with a single
health system, and two hospitals had implemented some
type of a prophylaxis program during the 2005–2006
period. Participating hospitals provided electronic patient-
level discharge-summary and billing records for 2005–
2006. Discharge-summary records contained demographic
data (age, gender, race), admission and discharge dates,
referral source and type of insurance. Primary and sec-
ondary codes for diagnoses and procedures (in Interna-
tional Classiﬁcations of Diseases, 9th revision, Clinical
Modiﬁcation [ICD-9-CM] format) and specialty of the
attending or admitting physician were also available.
Billing records provided daily information on inpatient
services provided and pharmacy data describing medica-
tion type, quantity, and dose. Hospital-level data included
bed count and indicators for teaching or non-teaching, rural
or urban, and for-proﬁt or non-proﬁt.
All patient records were de-identiﬁed by the hospitals in
compliance with the Privacy Rule of the Health Insurance
Portability and Accountability Act of 1996 [13]. The study
protocol was approved or exempted by the Institutional
Review Board governing each participating institution.
After the study, participating hospitals were provided the
pooled results for all 16 hospitals as well as the results
speciﬁc to their institution for purposes of comparison and
use in their quality improvement initiatives.
Study population
Patients 18 years and older at admission, who had an
inpatient stay C2 days between January 1, 2005 and
December 31, 2006, were eligible for inclusion. Patients
meeting one or more of the following were excluded from
the analyses: (1) transferred from another acute-care facility
where they may have already received thromboprophylaxis;
(2) pregnancy-related discharge diagnosis owing to pre-
cautions for anticoagulant use in pregnant women; (3) other
conditions where thromboprophylaxis could be contraindi-
cated were also excluded based on ICD-9-CM diagnosis
and procedure codes for active bleeding or indicating a
potentially high risk of bleeding due to certain liver dis-
eases, malignant hypertension, certain blood diseases,
active peptic ulcer and renal dysfunction; and (4) discharge
diagnosis of VTE in order to distinguish between VTE
prophylaxis and treatment.
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123Patients at risk
Patients were grouped into potentially at-risk cohorts based
on ACCP7 guidelines. We created mutually exclusive
groups of critical care, surgical, and medical patients based
on hospital discharge-summary and billing records. For
example a patient was ﬂagged as critical care if he/she had
a billing code indicative of time he/she spent in critical care
unit. Surgical and medical patients were identiﬁed using
ICD9-CM diagnosis and procedure codes indicative of the
surgery and condition of interest (see Table 1, technical
appendix). Patients were placed in the most severe group
for which they qualiﬁed (critical care being the highest in
severity and medical conditions being the lowest) For
instance a trauma patient who required surgery was
classiﬁed as surgery. Next, they were subclassiﬁed into
seven mutually exclusive diagnostic groups adapted from
ACCP7 (see Table 1)[ 1]. Surgical procedures were clas-
siﬁed as non-major (operations other than abdominal last-
ing\45 min) or major (any intra-abdominal operation and
any other operations lasting C45 min) [14]. Low, moderate
and high levels of surgical risk were deﬁned based on
ACCP7 risk factors [1]. The ﬁnal determination of at-risk
status and recommended thromboprophylaxis was based on
assessments of ‘‘additional risk factors’’ as speciﬁed in
ACCP7 [1]. Risk factors were identiﬁed using relevant
ICD9-CM diagnoses and procedure codes. Risk factors
such as smoking and immobility that are difﬁcult to
determine using ICD9-CM codes were not captured.
Study measures
The primary endpoint was the rate of appropriate throm-
boprophylaxis. This assessment was based upon ACCP7
recommendations for each cohort of patients at risk.
Appropriate thromboprophylaxis rates were determined
using four criteria: (1) whether the patient received any
thromboprophylaxis; (2) whether the appropriate type of
thromboprophylaxis (mechanical or pharmacologic) was
used; (3) whether the pharmacologic regimen (if any) was
given at a dose greater or equal to the minimum recom-
mended daily dose; and (4) whether the regimen was
administered for greater or equal to the recommended
number of days. ACCP7 recommends thromboprophylaxis
for the length of stay (LOS) for patients at risk of VTE.
However, for medical patients, duration was considered
sufﬁcient in this study if thromboprophylaxis was received
for LOS minus 1 day to accommodate partial days of stay.
For surgical patients, duration of LOS minus 2 days was
considered sufﬁcient to accommodate partial days of stay
and procedures for which thromboprophylaxis is not rec-
ommended on the day of surgery. Duration of prophylaxis
for pharmacologic agents was calculated by summing up
the number days for which a relevant billing code was
recorded. For mechanical prophylaxis, duration was cal-
culated as the total number of days between the ﬁrst billing
date during which a relevant billing code was recorded and
the discharge date. The rate of appropriate thrombopro-
phylaxis was calculated as the total number of appropri-
ately treated patients divided by the number of patients at
risk of VTE. Appropriate thromboprophylaxis rates were
determined for the full study period and for each calendar
quarter, as well as by primary attending physician spe-
cialty, hospital characteristics and LOS.
The study’s secondary endpoint was the proportion of
all hospitalized patients at risk of VTE. This was calculated
as the total number of patients at risk divided by the total
number of discharged patients.
Results
Patient population and characteristics
Of 258,556 patients for whom data were available, 135,954
(53%) met at least one exclusion criterion (Fig. 1). After
establishing the main diagnostic groups (critical care, sur-
gical, and medical) and applying the additional risk-factor
criteria speciﬁed in ACCP7, we identiﬁed 68,278 patients at
risk of VTE (26.4%). Of these, approximately equal per-
centages were critical care, surgical, and medical patients.
Most patients were female, elderly, and Caucasian with an
average LOS of 5.3 days, attended by internists and primary
care physicians, and insured by public (mostly Medicare
and Medicaid) or commercial health insurance (Table 1).
Rate of appropriate thromboprophylaxis
A total of 43,125 patients, or 63.2% of those at risk of
VTE, received some type of mechanical or pharmacologic
thromboprophylaxis (Table 2). This rate was greatest for
critical care patients, followed by surgical then medical.
However, only 12.9% of at-risk patients received appro-
priate type and dose and duration based on ACCP7 criteria
(20.4% of those receiving any thromboprophylaxis). The
rate of appropriate thromboprophylaxis was highest for
surgical patients, followed by critical care and medical
patients (17.9, 10.5, and 9.8%, respectively). Among doc-
umented physician specialties, the rate of appropriate
thromboprophylaxis was highest for orthopedics followed
by cardiology (32.0 and 18.3%, respectively), but still poor
overall. Across all categories, 87.1% of at-risk patients
received either no thromboprophylaxis or inappropriate
thromboprophylaxis.
The leading reason for failure to meet ACCP7 criteria
(Table 2) was no thromboprophylaxis at all (36.8% of
328 A. Amin et al.
123Table 1 Characteristics of patients at risk of VTE in 2005–2006, by major diagnostic group (n = 68,278)
Patient
characteristics
Critical
care
Surgery Medical Total
General,
vascular,
gynecologic,
laparoscopic,
and urologic
Orthopedic Neurosurgery Total
surgery
Trauma,
spinal
cord,
injuries,
and, burns
General
medical
 
Cancer Total
medical
Number of
patients at
risk of VTE
21,081 15,783 7,776 1,183 24,742 1,720 19,011 1,724 22,455 68,278
Age, %
18–39 10.2 18.7 3.3 11.2 13.5 18.5 0.0 1.0 1.5 8.5
40–49 12.1 21.6 8.4 10.1 16.9 13.5 11.8 6.9 11.6 13.7
50–59 18.6 20.2 20.6 14.9 20.1 16.8 15.5 15.0 15.5 18.1
60–69 20.7 16.2 26.2 23.1 19.7 13.2 18.6 24.0 18.6 19.7
70? 38.3 23.3 41.6 40.8 29.9 38.0 54.1 53.0 25.8 40.0
Race, %
Caucasian 81.8 77.0 88.5 80.6 80.8 85.1 84.2 87.9 84.6 82.3
African
American
7.7 10.2 3.6 4.6 7.9 3.8 7.3 6.1 6.9 7.5
Asian 0.9 1.1 0.4 0.7 0.8 0.8 0.8 0.6 0.8 0.8
Hispanic 6.8 9.2 4.6 11.7 7.9 8.7 5.3 3.8 5.5 6.8
Other 0.8 0.9 0.7 0.9 0.8 0.2 0.5 0.3 0.4 0.7
Not
documented
2.0 1.6 2.2 1.5 1.8 1.4 1.9 1.2 1.8 1.9
Gender, %
Male 51.1 35.8 36.8 50.9 36.8 41.0 40.1 45.1 40.6 42.5
Female 48.9 64.2 63.2 49.1 63.2 59.0 59.9 54.9 59.4 57.5
Not
documented
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Length of
staty, days(SD)
6.3 (6.4) 5.3 (5.2) 4.3 (2.5) 4.6 (5.2) 5.0 (4.5) 5.6 (4.8) 4.5 (2.9) 6.1 (4.4) 4.7 (3.3) 5.3 (4.9)
Referral source, %
Physician 61.6 56.2 58.3 65.3 57.3 69.7 56.9 56.7 57.9 58.8
ER 35.2 42.9 41.2 33.6 41.9 28.4 42.0 42.1 41.0 39.5
Other 3.1 0.9 0.6 1.0 0.8 1.9 1.0 1.2 1.1 1.6
Not
documented
0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0
Primary attending physician specialty
 ,%
Cardiology 22.9 1.7 0.1 0.3 1.1 0.2 6.8 4.6 6.1 9.5
Internal
medicine and
primary care
43.6 24.0 7.4 4.3 17.9 26.7 76.5 55.7 71.1 43.3
Neurology 8.6 0.9 6.1 54.1 5.0 1.6 0.7 0.2 0.8 4.7
Oncology 0.7 3.0 0.1 0.5 1.9 0.1 0.1 18.3 1.5 1.4
Orthopedic 1.9 1.6 72.8 14.0 24.5 34.4 0.6 1.3 3.3 10.6
Surgery 9.4 37.6 0.8 3.6 24.4 28.0 1.1 3.1 3.3 12.8
Other 9.4 28.2 10.2 22.4 22.3 4.1 7.1 10.3 7.1 13.3
Not
documented
3.7 3.1 2.5 0.8 2.8 4.8 7.0 6.6 6.8 4.4
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123at-risk patients). Additionally, patients frequently received
thromboprophylaxis regimens that were of the inappropri-
ate type (25.4% of at-risk patients); appropriate type but
inadequate dose and insufﬁcient duration (13.9%); appro-
priate type and sufﬁcient duration but inadequate dose
(8.3%); and appropriate type and adequate dose but
insufﬁcient duration (2.7%). Of patients who received any
thromboprophylaxis, 25.3% received it on only 1 day,
16.1% on 2 days and 15.2% on 3 days; it was most often
initiated on the ﬁrst day of the stay (67.4%).
Over the 2-year study period, the overall (critical care,
surgery and medical conditions combined) quarterly rates
of appropriate thromboprophylaxis reﬂected modest
improvement, from 11.6% in the ﬁrst quarter of 2005 to
14.5% in the last quarter of 2006. However the rate of
improvement over time varied across the individual cohorts
(Fig. 2). The rate of appropriate thromboprophylaxis varied
according to hospital characteristics. Higher rates of
appropriate thromboprophylaxis were observed for large
hospitals compared to small hospitals (Table 3). Patients
were also more likely to receive thromboprophylaxis based
on ACCP7 in urban, teaching, and for-proﬁt hospitals.
Discussion
This study demonstrates that the 7th ACCP guidelines for
type, dose and duration of thromboprophylaxis were not
implemented to a high degree in participating hospitals.
While nearly two-thirds of patients at risk of VTE received
some form of thromboprophylaxis, fewer than one in seven
(or about one in ﬁve of those who received any thrombo-
prophylaxis) received the appropriate type, dose and
duration. The proportions of patients receiving appropriate
Table 1 continued
Patient
characteristics
Critical
care
Surgery Medical Total
General,
vascular,
gynecologic,
laparoscopic,
and urologic
Orthopedic Neurosurgery Total
surgery
Trauma,
spinal
cord,
injuries,
and, burns
General
medical
 
Cancer Total
medical
Payer type, %
Public § 48.4 32.5 48.1 47.3 38.1 44.0 63.8 62.8 62.2 49.2
Commercial 43.7 59.3 49.1 46.3 55.5 39.6 30.9 34.6 31.9 44.1
No
insurance
7.2 7.0 0.8 1.7 4.8 10.9 4.8 2.2 5.1 5.6
Other 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Not
documented
0.8 1.1 2.0 4.6 1.6 5.5 0.5 0.4 0.9 1.1
Number of additional VTE risk factors**, %
No risk
factors
12.2 24.0 51.2 65.1 34.5 0.3 44.2 0.0 37.5 28.6
1 or more
risk factors
87.8 76.0 48.8 34.9 65.5 99.7 55.8 100.0 62.5 71.4
1 risk factor 34.4 41.5 36.6 25.3 39.2 71.6 41.4 1.0 40.6 38.2
2? risk
factors
53.4 34.5 12.2 9.6 26.3 28.1 14.4 99.0 21.9 33.2
Classiﬁcations and risk factors are adapted from the 7th ACCP Guidelines [1]
  General medical includes heart failure, severe respiratory disease, acute myocardial infarction, stroke, and severe infectious disease
 Cardiology: cardiology, cardiovascular disease, or cardiology/electrophysiology; internal medicine and primary care: family practice, family nurse practitioner,
general practice, hospitalist, or internal medicine; oncology: oncology or radiation oncology; surgery: cardiothoracic surgery, general surgery, neurosurgery, plastic
and reconstructive surgery, or unspeciﬁed surgical specialty; orthopedic: orthopedic or orthopedic surgery; other: adult nurse practitioner, anesthesiology, critical
care, dentist, dermatology, emergency medicine, family nurse practitioner, gastroenterology, hematology, nephrology, ophthalmology, pathology, physical medicine/
rehabilitation, physician assistant, podiatry, pulmonary, rheumatology, urology, pediatric medicine, radiology, or ear/nose/throat; not documented: could not be
determined from the data due to missing values
§ Public payers include medicare, medicaid, veteran’s health, and Indian health service
** Deﬁned as any additional risk factors beyond the actual diagnostic groups. Risk factors were determined using primary and secondary diagnosis and procedure
codes. In addition to the risk factors deﬁned by each of the seven diagnostic groups, 71.4% of at-risk patients had at least one additional risk factor for VTE and
33.2% had two or more risk factors. The top three risk factors for all patients were heart/respiratory failure (34.7%), acute medical illness (25.7%) and surgery
(17.3%)
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123thromboprophylaxis were alarmingly low for every diag-
nostic group, physician specialty, hospital category, and
time period studied.
Hospitals may have intended to implement ACCP7 to
varying degrees, and this may partially explain the low
levels of appropriate thromboprophylaxis observed in our
study. However, the use of alternative guidelines or stan-
dards for thromboprophylaxis is unlikely to explain the
absence of any thromboprophylaxis in 37% of at-risk
patients. Indeed, the high rate of omission of any form of
thromboprophylaxis in medical and surgical patients found
in this study is consistent with the ﬁndings of other studies
[5, 11, 12, 16]. In those patients who did get thrombo-
prophylaxis, the regimen did not reﬂect ACCP7 guidelines
nearly 80% of the time, and the leading cause was inap-
propriate type (e.g., giving mechanical only when phar-
macologic was indicated). Thus, our ﬁndings demonstrate a
persistent and worrisome gap in the performance of evi-
dence-based thromboprophylaxis for hospitalized patients
at participating institutions.
VTE START is, to our knowledge, the only study that
has assessed the appropriateness of thromboprophylaxis in
multiple US hospitals using the 7th ACCP guidelines for
type, dose, and duration. Previous retrospective studies
using patient chart reviews have shown that 25 to 84% of
hospitalized patients are at risk of VTE and that only 23 to
46% of these patients receive any form of thrombopro-
phylaxis [4–8]. However, these studies were based on
relatively small samples of patients (range: 100–4124)
with medical conditions and relied on the 6th ACCP or
non-ACCP guidelines. Two recent, large international
registries, using chart review, assessed the use of
thromboprophylaxis against ACCP7 [9, 10]. However, the
ENDORSE study of 68,183 patients in 32 countries [9] did
not include duration of thromboprophylaxis, and the
IMPROVE study of 15,156 patients in 12 countries [10]
did not assess the appropriateness of the type of the
thromboprophylaxis received. Two other recent studies
[11, 12] used electronic databases of patient records to
assess the appropriateness of thromboprophylaxis against
the 6th rather than the 7th ACCP guidelines. Yu and col-
leagues [11] reported appropriate thromboprophylaxis in
only 13.3% of patients across a similar range of diagnostic
groups. Amin and colleagues [12] found the rate of
appropriate thromboprophylaxis to be 33.9% among high-
risk medical patients. It is worth noting that there is no
signiﬁcant difference between the 6th and the 7th ACCP
guidelines in terms of the criteria for appropriate prophy-
laxis, therefore the bases of the results from our study
should be comparable to the bases of the results obtained
from those published studies.
Our results should be interpreted in light of several
limitations. First, we employed discharge-summary and
billing data to assess risk status and appropriateness of
thromboprophylaxis. While such electronic data allow for
rapid and efﬁcient analysis of all patients in an institution,
there is the possibility of measurement error because cer-
tain risk factors cannot be fully assessed based on dis-
charge and billing records. This may have led to inaccurate
assumptions about a patient’s at-risk status or appropriate
thromboprophylaxis regimen. For example, we determined
that 26% of all hospitalized patients were at risk of VTE
and had no apparent contraindications for thrombopro-
phylaxis. These results are similar to other studies using
Fig. 1 Construction of study
sample
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123hospital discharge-summary and billing data (13–31%)[11,
15] but at the lower end of the range of results from chart-
based evaluations (25–84%)[4–8, 16]. This may be due to
our large sample representing more categories of patients
than previous studies, but it may also reﬂect our liberal
exclusion criteria for potential bleeding risk, which
Fig. 2 Patients at risk of VTE
who received appropriate
prophylaxis by diagnostic group
over time (n = 68,278)
Table 3 Rates of any and appropriate VTE prophylaxis among patients at risk of VTE, by hospital characteristics (n = 68,278)
Hospital
characteristic
Total at
risk, N
Received
any
prophylaxis
Received no
prophylaxis
Received
appropriate
type, dose,
and duration
of prophylaxis
% of N at risk
Reason for inappropriate prophylaxis, percent of N at risk
N % N % Inappropriate
type
Appropriate
type and dose
but insufﬁcient
duration
Appropriate
type and
duration but
inappropriate
dose
Appropriate
type but
insufﬁcient
duration
Number of beds
0–100 5,567 2,825 50.7 2,742 49.3 11.9 24.9 1.0 4.9 8.0
101–500 36,957 21,242 57.5 15,715 42.5 11.3 22.1 2.9 6.7 14.5
501–1000 25,754 19,058 74.0 6,696 26.0 15.4 30.2 2.8 11.4 14.2
1000? – – 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Geographic location
Urban 59,740 39,523 66.2 20,217 33.8 13.6 26.0 3.0 9.2 14.3
Rural 8,538 3,602 42.2 4,936 57.8 8.4 20.7 0.5 1.9 10.6
Teaching status
Teaching 10,791 6,191 57.4 4,600 42.6 15.6 19.1 2.1 3.0 17.6
Non-
Teaching
57,487 36,934 64.2 20,553 35.8 12.4 26.5 2.8 9.3 13.2
Type
Not-for-
proﬁt
57,487 36,934 64.2 20,553 35.8 12.4 26.5 2.8 9.3 13.2
For-proﬁt 10,791 6,191 57.4 4,600 42.6 15.6 19.1 2.1 3.0 17.6
Payer mix
Public 33,601 20,507 61.0 13,094 39.0 10.3 27.7 1.8 7.7 13.5
Commercial 30,088 19,826 65.9 10,262 34.1 15.5 23.1 3.7 8.8 14.8
Other 4,589 2,792 60.8 1,797 39.2 15.6 22.8 2.8 9.3 10.4
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123increased the number of patients for whom thrombopro-
phylaxis was contraindicated and reduced the proportion at
risk of VTE. Our approach is consistent with previous
studies using discharge-summary and billing data[11, 12],
and reﬂects a desire to under-estimate rather than over-
estimate the proportion of patients at risk of VTE. With this
in mind, it is worth noting that we had no access to
patients’ clinical history such as recent (\30 days) GI
bleeding, therefore we might have been overestimated the
at risk population as described herein. Similarly, we may
have overestimated the number of patients receiving
appropriate thromboprophylaxis because we imposed no
upper bound on dose and a low threshold for appropriate
duration. Both of these criteria reﬂect our intent to be as
liberal as possible where there was uncertainty in our
ability to determine appropriate thromboprophylaxis.
Finally, our small sample of 16 hospitals was not intended
to be nationally representative, and the fact that 13 of them
were part of a single hospital system may have reduced the
variance within the sample. Further, the observed variation
in the rate of prophylaxis across the participating hospitals
are likely to be confounded due the fact that some of these
hospitals had some initiative in place for improving pro-
phylaxis. The extent to which the low levels of thrombo-
prophylaxis found in these hospitals reﬂect the levels in
other US hospitals is unknown.
Our results demonstrate an alarmingly low degree of
implementation of the 7th ACCP guidelines and imply the
need for urgent action by physicians and health systems to
assess risk and deliver appropriate thromboprophylaxis.
Interventions in the form of educational programs, risk
stratiﬁcation, critical pathways and alert tools have been
effective in increasing the rate of thromboprophylaxis [8,
11, 17–19]. An additional strength of this project was the
delivery of benchmarking reports to participating hospitals,
for use in the development and evaluation of their own
quality improvement initiatives. Institutions may ﬁnd that
analyzing their administrative databases on all patients is a
more efﬁcient and comprehensive method than manual
chart abstraction of small samples of patients for assessing
thromboprophylaxis rates and the impact of quality
improvement initiatives.
Conclusions
This study demonstrates the signiﬁcant gap between evi-
dence-based thromboprophylaxis recommendations and
actual clinical practice in a large sample of hospitalized
patients. More than 25% of hospitalized patients were at
risk of VTE, but fewer than one in seven of these patients
received thromboprophylaxis that met criteria for recom-
mended type, dose and duration. We recommend intensive
efforts to improve the degree of implementation of current
guidelines for appropriate thromboprophylaxis.
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Appendix
See Tables 4, 5
Table 4 Criteria for determining appropriate prophylaxis by study cohort
Study cohort Additional stratiﬁcation Appropriate prophylaxis
Critical care
Critical care • All patients Type: LDUH or LMWH
• Major trauma or orthopedic surgery Dose: See minimum prophylaxis dose in Table 5, technical
appendix.
Duration: LOS-1 (medical) LOS-2 (surgical)
Type: LMWH
Dose: See minimum prophylaxis dosein Table 5, technical
appendix.
Duration: LOS -1 (trauma) LOS-2 (orthopedic surgery)
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Study cohort Additional stratiﬁcation Appropriate prophylaxis
General, transplant, vascular, gynecologic, urologic, laparoscopic surgery
General • Non-major surgery, age less than 40, additional risk
factors, or
Type: LDUH, LMWH, GCS or IPC
Dose: LDUH (10,000 units/day); LMWH (B3,400 IU/day)
• Non-major surgery, age 40–60, regardless of risk
factors, or
Duration: LOS-2
• Major surgery, age less than 40, regardless of
risk factors
• Non-major surgery, age 60 or older, and with or
without risk factors, or
Type: LDUH, LMWH
Dose: LDUH (15,000 units/day), LMWH ([3,400 IU/day)
• Major surgery, greater than 60 years of age, and
with no risk factors, or
Duration: LOS-2
• Major surgery in patients\40, additional risk
factors, or
• Major surgery in patients between the ages of 40–60
• Major surgery with greater than 60 years of age with
additional risk factors
Type: LDUH ? (GCS or IPC), or LMWH ? (GCS or IPC)
Dose: LDUH (15,000 units/day), LMWH ([3,400 IU/day)
Duration: LOS-2
Transplant Note: This is part of general surgery and will be
treated as such
Same as general surgery
Vascular None Type: LDUH or LMWH
Dose: See minimum prophylaxis dose in Table 5, technical
appendix.
Duration: LOS-2
Gynecologic • Major GYN surgery (benign disease) and no
additional risk factors
Type: LDUH, LMWH, or IPC
Dose: LDUH (10,000 units/day) LMWH(B3,400 IU/day)
Duration: LOS-2
• Major GYN surgery with malignant GYN neoplasms,
regardless of risk factors
Type: LDUH, LMWH, IPC or LDUH/LMWH with GCS/
IPC
Dose: LDUH 15,000 units/day) LMWH ([3,400 IU/day) • Major GYN surgery(benign disease) and additional
risk factors Duration: LOS-2
• Laproscopic GYN procedures with additional
risk factors
Type: LDUH, LMWH, IPC, or GCS
Dose: See minimum prophylaxis dose in Table 5, technical
appendix.
Duration: LOS-2
Urologic • One or no risk factors Type: LDUH or GCS or IPC
Dose: LDUH (10,000 units/day)
Duration: LOS-2
• Two or more risk factors Type: LDUH ? GCS or IPC, LMWH ? GCS or IPC
Dose: LDUH (10,000 units/day), LMWH (See minimum
prophylaxis dose in Table 5, technical appendix.)
Duration: LOS-2
Laparoscopic None Type: LDUH, LMWH, GCS, IPC
Dose: See minimum prophylaxis dose in Table 5, technical
appendix.
Duration: LOS-2
Orthopedic Surgery
Elective hip
arthroplasty
None Type: LMWH, fondaparinux or VKA
Dose: LMWH ([3,400 IU/day), Fondaparinux (2.5 mg/
day), VKA (regardless of the dose)
Duration: LOS-2
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Elective knee
arthroplasty
None Type: LMWH, Fondaparinux or VKA
Dose: LMWH ([3,400 IU/day), Fondaparinux (2.5 mg/
day), VKA (regardless of the dose)
Duration: LOS-2
Knee arthroscopy None Type: LMWH
Dose: See minimum prophylaxis dose in Table 5, technical
appendix.
Duration: LOS-2
Hip fracture surgery Type: LMWH, fondaparinux, VKA, LDUH
Dose: LMWH([3,400/day) Fodaparinux (2.5 mg/day)
VKA (regardless of dose) LDUH (10,000 units/day)
Duration: LOS-2
Elective spine surgery • One or no additional risk factors Type: LDUH, LMWH, IPC, or GCS
Dose: See minimum prophylaxis dose in Table 5, technical
appendix.
Duration: LOS-2
• Two or more risk factors Type: LDUH ? (any GCS or IPC), LMWH ? (any GCS or
IPC)
Dose: See minimum prophylaxis dose in Table 5, technical
appendix.
Duration: LOS-2
Neurosurgery
Neurosurgery • Age less than 40 with additional risk factor Type: LMWH, UFH, IPC or GCS
Dose: See minimum prophylaxis dose in Table 5, technical
appendix.
Duration: LOS-2
• Age 40 or above regardless of risk factors Type: LMWH ? (IPC or GCS), or UFH ? (IPC or GCS)
Dose: See minimum prophylaxis dose in Table 5, technical
appendix.
Duration: LOS-2
Trauma, spinal cord injuries, burns
Trauma None Type: LMWH, GCS or IPC
Dose: See minimum prophylaxis dose in Table 5, technical
appendix.
Duration: LOS-1
Spinal cord injuries None Type: LMWH, LMWH ? IPC, or LDUH ? IPC
Dose: See minimum prophylaxis dose in Table 5, technical
appendix.
Duration: LOS-1
Burns None Type: LDUH or LMWH
Dose: See minimum prophylaxis dose in Table 5, technical
appendix.
Duration: LOS-1
Acutely Ill medical patients
Heart failure None Type: LDUH or LMWH
Dose: See minimum prophylaxis dose in Table 5, technical
appendix.
Duration: LOS-1
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Severe respiratory
infection
None Type: LDUH or LMWH
Dose: See minimum prophylaxis dose in Table 5, technical
appendix.
Duration: LOS-1
Acute myocardial
infraction
None Type: LDUH or LMWH
Dose: See minimum prophylaxis dose in Table 5, technical
appendix.
Duration: LOS-1
Stroke None Type: LDUH or LMWH
Dose: See minimum prophylaxis dose in Table 5, technical
appendix.
Duration: LOS-1
Severe infectious
disease
None Type: LDUH or LMWH
Dose: See minimum prophylaxis dose in Table 5, technical
appendix.
Duration: LOS-1
Cancer
Without surgery
(medical
conditions)
Assessed according to the accompanying medical condition
Table 5 Label based dosing for pharmacologic prophylaxis and the minimum dose per day utilized in the study
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